Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 597-601 , December 2009

Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity

  • Sara C. Erridge

      Affiliations

    • Edinburgh Centre for Neuro-Oncology, University of Edinburgh, UK
    • Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
    • Corresponding Author InformationCorresponding author. Address: Edinburgh Centre for Neuro-Oncology, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK.
    • ,
  • David S. Conkey

      Affiliations

    • Belfast City Hospital, Northern Ireland Cancer Centre, UK
    • ,
  • Diane Stockton

      Affiliations

    • ISD, NHS National Services Scotland, Edinburgh, UK
    • ,
  • Mark W.J. Strachan

      Affiliations

    • Metabolic Unit, University of Edinburgh, UK
    • ,
  • Patrick F.X. Statham

      Affiliations

    • Edinburgh Centre for Neuro-Oncology, University of Edinburgh, UK
    • ,
  • Ian R. Whittle

      Affiliations

    • Edinburgh Centre for Neuro-Oncology, University of Edinburgh, UK
    • ,
  • Robin Grant

      Affiliations

    • Edinburgh Centre for Neuro-Oncology, University of Edinburgh, UK
    • ,
  • Gillian R. Kerr

      Affiliations

    • Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
    • ,
  • Anna Gregor

      Affiliations

    • Edinburgh Centre for Neuro-Oncology, University of Edinburgh, UK
    • Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK

Received 15 May 2009 ,Revised 17 September 2009 ,Accepted 29 September 2009.

References 

  1. Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol. 1993;38:571–578
  2. Dekkers OM, Pereira AM, Roelfsema F, et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2006;91:1796–1801
  3. Greenman Y, Ouaknine G, Veshchev I, et al. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin Endocrinol. 2003;58:763–769
  4. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab. 2005;90:800–804
  5. Fisher BJ, Gaspar LE, Noone B. Radiation therapy of pituitary adenoma: delayed sequelae. Radiology. 1993;187:843–846
  6. MacDougall R, Kerr G, Duncan W. Incidence of sarcoma in patients treated with fast neutrons. Int J Radiat Oncol Biol Phys. 2006;66:824
  7. Becker G, Kocher M, Kortmann RD, et al. Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol. 2002;178:173–186
  8. Brada M, Jankowska P. Radiotherapy for pituitary adenomas. Endocrinol Metab Clin North Am. 2008;37:263–275
  9. Snead F, Amdur R, Morris C, Mendenhall W. Long-term outcomes of radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys. 2008;71:994–998
  10. Loeffler JS, Nachtigall LB. Is fractionated stereotactic radiotherapy effective in pituitary adenomas?. Nat Clin Pract Oncol. 2005;2:548–549
  11. Voges J, Kocher M, Runge M, et al. Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study. Cancer. 2006;107:1355–1364
  12. Mackley HB, Reddy CA, Lee SY, et al. Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland clinic experience. Int J Radiat Oncol Biol Phys. 2007;67:232–239
  13. Gittoes NJ, Bates AS, Tse W, et al. Radiotherapy for non-function pituitary tumours. Clin Endocrinol. 1998;48:331–337
  14. van den Bergh AC, van den Berg G, Schoorl MA, et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys. 2007;67:863–869
  15. Turner H, Stratton I, Byrne J, Adams C, Wass J. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation – a follow-up study. Clin Endocrinol. 1999;51:281–284
  16. Littley M, Shalet S, Beardwell C, Robinson E, Sutton M. Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol. 1989;31:363–373
  17. McCollough WM, Marcus RB, Rhoton AL, Ballinger WE, Million RR. Long-term follow-up of radiotherapy for pituitary adenoma: the absence of late recurrence after greater than or equal to 4500cGy. Int J Radiat Oncol Biol Phys. 1991;21:607–614
  18. Tsang RW, Brierley JD, Panzarella T, et al. Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 1994;30:557–565
  19. Brada M, Ashley S, Ford D, et al. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol. 2002;57:713–717
  20. Holmer H, Svensson J, Rylander L, et al. Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone. J Clin Endocrinol Metab. 2007;92:3560–3567
  21. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357:425–431
  22. Norberg L, Johansson R, Rasmuson T. Pituitary adenomas in norther Sweden: a study on therapy choices and the risk of second primary tumours. Clin Endocrinol. 2007;68:780–785

☆ Funding: Dr. Conkey was funded by The University of Edinburgh Brain Tumour Research Fund and The University of Edinburgh Cancer Research Centre funded the Cancer Registry data linkage.

PII: S0167-8140(09)00559-3

doi: 10.1016/j.radonc.2009.09.011

Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 597-601 , December 2009

Article Tools